Overview

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate Tablets combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Zhou Fuxiang

Collaborators:

Hanchuan City people's Hospital
Huangshi Central Hospital, China
Hubei Cancer Hospital
Shiyan Taihe Hospital
The Central Hospital of Huanggang
The first hospital of Zaoyang
Tianmen People's Hospital
Xianning Central Hospital
Yangxin People's Hospital

Treatments:

Apatinib
Docetaxel
Tegafur